EVMN Evommune, Inc.
USHealthcareAs of 2026-07-10 16:00
Why EVMN matters now
Evommune, Inc. (EVMN) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.21 with -2.22% on the session and $187.1M in market capitalization; recent performance reads 1-month +1.14% and YTD +24.77%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-21.7M, and EPS of $-0.64. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -26.6%.
The latest indexable market news headline is "Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $50.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.36
P/S
30.25
EV/EBITDA
-3.53
DCF Value
$-75.52
FCF Yield
-26.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.8%
Operating Margin
-899.9%
Net Margin
-759.9%
ROE
-195.2%
ROA
-23.6%
ROIC
-28.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-21.7M | $-0.64 |
| Q4 2025 | $0.00 | $-28.3M | $-0.90 |
| FY 2025 | $13.0M | $-68.9M | $-2.18 |
| Q3 2025 | $10.0M | $-12.5M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$48.40
Target (Median)
$50.00
Target Range
$40.00 - $55.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.10
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.